|
US3262977A
(en)
*
|
1962-03-10 |
1966-07-26 |
Chinoin Gyogyszer Es Vegyeszet |
N-aralkyl-1, 1-diphenyl-propylamine derivatives
|
|
NL296693A
(US07368562-20080506-C00013.png)
*
|
1962-08-16 |
|
|
|
|
FR95908E
(fr)
*
|
1963-11-09 |
1972-01-31 |
Degussa |
Procédé de préparation de nouvelles aminocétones et des alcools secondaires correspondants.
|
|
US3457354A
(en)
*
|
1965-09-21 |
1969-07-22 |
Merck & Co Inc |
Treatment of hypertension with 2-hydroxy (or amino) - 4,5 - dihydroxyphenethylamine derivatives
|
|
US3895057A
(en)
*
|
1967-10-13 |
1975-07-15 |
Dainippon Pharmaceutical Co |
Aminoalkanols and their pharmaceutically acceptable acid-addition salts, and production thereof
|
|
US4329367A
(en)
*
|
1974-08-05 |
1982-05-11 |
Ciba-Geigy Corporation |
1-(Aralkoxyphenyl)-2-(bis-arylalkylamino)-alkanes
|
|
DE2902172C2
(de)
*
|
1979-01-20 |
1984-05-10 |
UOP Inc., 60016 Des Plaines, Ill. |
Verfahren zur Herstellung eines N,N'-Dialkylphenylendiamins
|
|
WO1983003755A1
(en)
*
|
1982-04-23 |
1983-11-10 |
Caola Kozmetikai És Háztartäsvegyipari Vállalat |
Novel cosmetic compositions containing prenylamine and a process for their preparation
|
|
NZ215753A
(en)
*
|
1985-04-16 |
1989-10-27 |
Hoffmann La Roche |
Phenethanolamine derivatives and pharmaceutical compositions
|
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
|
AR032643A1
(es)
*
|
2001-01-26 |
2003-11-19 |
Schering Corp |
Combinaciones de inhibidor(es) de absorcion de esterol con agente(s) cardiovascular(es) para el tratamiento de condiciones vasculares
|
|
PT1353694E
(pt)
*
|
2001-01-26 |
2008-03-12 |
Schering Corp |
Combinações de ezetimiba com aspirina para o tratamento de doenças vasculares
|
|
US7071181B2
(en)
*
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
|
US20020183305A1
(en)
*
|
2001-01-26 |
2002-12-05 |
Schering Corporation |
Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
|
|
SI1353696T1
(sl)
*
|
2001-01-26 |
2007-04-30 |
Schering Corp |
Kombinacije aktivatorja(-ev) peroksisomskega proliferatorja aktivirajocega receptorja (PPAR) in inhibitorja(-ev) absorpcije sterola in oblike zdravljenja za vaskularne indikacije
|
|
PL205343B1
(pl)
*
|
2001-01-26 |
2010-04-30 |
Schering Corp |
Zastosowanie inhibitora wchłaniania sterolu
|
|
CA2434033A1
(en)
*
|
2001-01-26 |
2002-08-01 |
Schering Corporation |
Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
|
CA2447884A1
(en)
*
|
2001-05-25 |
2002-12-05 |
Schering Corporation |
Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
|
|
PT1427409E
(pt)
*
|
2001-09-21 |
2008-11-27 |
Schering Corp |
Métodos para tratar ou para impedir a inflamação vascular utilizando inibidor(es) de absorção de esteróis
|
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
|
DK1429756T3
(da)
*
|
2001-09-21 |
2007-03-19 |
Schering Corp |
Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer
|
|
US7056906B2
(en)
*
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
|
RS20050106A
(en)
|
2002-08-19 |
2007-11-15 |
Pfizer Products Inc., |
Combination therapy for hyperproliferative diseases
|
|
CA2504916A1
(en)
*
|
2002-11-06 |
2004-05-27 |
Schering Corporation |
Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
|
|
EP1601668B1
(en)
|
2003-03-07 |
2008-08-27 |
Schering Corporation |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
|
|
US7192944B2
(en)
*
|
2003-03-07 |
2007-03-20 |
Schering Corp. |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
|
ES2318274T3
(es)
|
2003-03-07 |
2009-05-01 |
Schering Corporation |
Compuestos de azetidinona sustituida, formulaciones y uso de los mismos para el tratamiento de hipercolesterolemia.
|
|
US7459442B2
(en)
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
|
US20050096307A1
(en)
*
|
2003-11-05 |
2005-05-05 |
Schering Corporation |
Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
|
|
US20060147520A1
(en)
*
|
2004-07-26 |
2006-07-06 |
Curtis Ruegg |
Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
|
|
US20060063803A1
(en)
*
|
2004-09-23 |
2006-03-23 |
Pfizer Inc |
4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
|
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
|
EP1951253A2
(en)
*
|
2005-10-26 |
2008-08-06 |
Cotherix, Inc. |
Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
|
|
EP2351569B1
(en)
|
2005-10-26 |
2012-08-22 |
Asahi Kasei Pharma Corporation |
Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
|
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
|
US7919506B2
(en)
|
2006-03-10 |
2011-04-05 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
|
ATE547394T1
(de)
|
2006-12-01 |
2012-03-15 |
Bristol Myers Squibb Co |
N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
|
|
WO2008151257A2
(en)
|
2007-06-04 |
2008-12-11 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
AU2009256157B2
(en)
|
2008-06-04 |
2014-12-18 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
EP2321341B1
(en)
|
2008-07-16 |
2017-02-22 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
WO2012037665A1
(en)
|
2010-09-24 |
2012-03-29 |
Oral Delivery Technology Ltd. |
Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
|
|
WO2014151206A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
|
AU2014235209B2
(en)
|
2013-03-15 |
2018-06-14 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists combined with other drugs
|
|
AU2014255381A1
(en)
|
2013-04-17 |
2015-10-08 |
Pfizer Inc. |
N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
|
|
WO2014197720A2
(en)
|
2013-06-05 |
2014-12-11 |
Synergy Pharmaceuticals, Inc. |
Ultra-pure agonists of guanylate cyclase c, method of making and using same
|
|
WO2016055901A1
(en)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Substituted amide compounds
|
|
JOP20210193A1
(ar)
|
2019-01-18 |
2023-01-30 |
Astrazeneca Ab |
مثبطات pcsk9 وطرق استخدامها
|
